Ronald L Thibert

List of Publications by Year
in descending order

43 papers	1,569 citations	394421 19 h-index	315739 38 g-index
45 all docs	45 docs citations	45 times ranked	1959 citing authors

#	Article	IF	Citations
1	Early and effective treatment of <scp>KCNQ</scp>2 encephalopathy. Epilepsia, 2015, 56, 685-691.	5.1	229
2	Neurologic Manifestations of Angelman Syndrome. Pediatric Neurology, 2013, 48, 271-279.	2.1	150
3	The Interstitial Duplication 15q11.2â€q13 Syndrome Includes Autism, Mild Facial Anomalies and a Characteristic EEG Signature. Autism Research, 2013, 6, 268-279.	3.8	130
4	Epilepsy in Angelman syndrome: A questionnaireâ€based assessment of the natural history and current treatment options. Epilepsia, 2009, 50, 2369-2376.	5.1	115
5	A survey of seizures and current treatments in 15q duplication syndrome. Epilepsia, 2014, 55, 396-402.	5.1	80
6	If not Angelman, what is it? a review of Angelmanâ€like syndromes. American Journal of Medical Genetics, Part A, 2014, 164, 975-992.	1.2	80
7	Delta rhythmicity is a reliable EEG biomarker in Angelman syndrome: a parallel mouse and human analysis. Journal of Neurodevelopmental Disorders, 2017, 9, 17.	3.1	74
8	Angelman syndrome in adulthood. American Journal of Medical Genetics, Part A, 2015, 167, 331-344.	1.2	68
9	Epilepsy and the sleepâ€“wake patterns found in Angelman syndrome. Epilepsia, 2009, 50, 2497-2500.	5.1	65
10	Low glycemic index treatment for seizures in Angelman syndrome. Epilepsia, 2012, 53, 1498-1502.	5.1	52
11	Identification of a distinct developmental and behavioral profile in children with Dup15q syndrome. Journal of Neurodevelopmental Disorders, 2016, 8, 19.	3.1	47
12	Low glycemic index treatment for seizure control in Angelman syndrome: A case series from the Center for Dietary Therapy of Epilepsy at the Massachusetts General Hospital. Epilepsy and Behavior, 2017, 68, 45-50.	1.7	43
13	Angelman syndrome genotypes manifest varying degrees of clinical severity and developmental impairment. Molecular Psychiatry, 2021, 26, 3625-3633.	7.9	41
14	Validation of a smartphone-based EEG among people with epilepsy: A prospective study. Scientific Reports, 2017, 7, 45567.	3.3	39
15	Novel Compound Heterozygous Mutations Expand the Recognized Phenotypes of FARS2-Linked Disease. Journal of Child Neurology, 2016, 31, 1127-1137.	1.4	36
16	Seizure treatment in Angelman syndrome: A case series from the Angelman Syndrome Clinic at Massachusetts General Hospital. Epilepsy and Behavior, 2016, 60, 138-141.	1.7	32
17	Angelman syndrome in adolescence and adulthood: A retrospective chart review of 53 cases. American Journal of Medical Genetics, Part A, 2018, 176, 1327-1334.	1.2	27
18	Delta power robustly predicts cognitive function in Angelman syndrome. Annals of Clinical and Translational Neurology, 2021, 8, 1433-1445.	3.7	23

#	Article	IF	Citations
19	Prevalence of gastrointestinal symptoms in Angelman syndrome. American Journal of Medical Genetics, Part A, 2017, 173, 2703-2709.	1.2	21
20	Behavioral characterization of dup15q syndrome: Toward meaningful endpoints for clinical trials. American Journal of Medical Genetics, Part A, 2020, 182, 71-84.	1.2	21
21	Hippocampal Abnormalities in Magnetic Resonance Imaging (MRI) of 15q Duplication Syndromes. Journal of Child Neurology, 2015, 30, 333-338.	1.4	20
22	Myoclonus in Angelman syndrome. Epilepsy and Behavior, 2018, 82, 170-174.	1.7	20
23	Diazepam for outpatient treatment of nonconvulsive status epilepticus in pediatric patients with Angelman syndrome. Epilepsy and Behavior, 2018, 82, 74-80.	1.7	15
24	How do we diagnose and treat epilepsy with myoclonic-atonic seizures (Doose syndrome)? Results of the Pediatric Epilepsy Research Consortium survey. Epilepsy Research, 2018, 144, 14-19.	1.6	14
25	A multidisciplinary approach and consensus statement to establish standards of care for Angelman syndrome. Molecular Genetics & Genomic Medicine, 2022, 10, e1843.	1.2	14
26	Gastrointestinal problems in 15q duplication syndrome. European Journal of Medical Genetics, 2015, 58, 191-193.	1.3	13
27	The STARS Phase 2 Study. Neurology, 2021, 96, e1024-e1035.	1.1	12
28	Medication prescribing and patient-reported outcome measures in people with epilepsy in Bhutan. Epilepsy and Behavior, 2016, 59, 122-127.	1.7	11
29	Electroencephalographic patterns during sleep in children with chromosome 15q11.2-13.1 duplications (Dup15q). Epilepsy and Behavior, 2016, 57, 133-136.	1.7	11
30	Buspirone for the treatment of anxiety-related symptoms in Angelman syndrome. Psychiatric Genetics, 2019, 29, 51-56.	1.1	11
31	The Use of Magnetic Resonance Spectroscopy in the Evaluation of Pediatric Patients With Seizures. Pediatric Neurology, 2016, 58, 57-66.	2.1	9
32	Parent Description of Anxiety in Angelman Syndrome. Journal of Autism and Developmental Disorders, 2022, 52, 3612-3625.	2.7	8
33	Levodopa Response Reveals Sepiapterin Reductase Deficiency in a Female Heterozygote with Adrenoleukodystrophy. JIMD Reports, 2011, 3, 79-82.	1.5	6
34	Reversible uncal herniation in a neonate with a large MCA infarct. Brain and Development, 2009, 31, 763-765.	1.1	5
35	Longitudinal EEG model detects antisense oligonucleotide treatment effect and increased UBE3A in Angelman syndrome. Brain Communications, 2022, 4, .	3.3	5
36	A Rare Inherited 15q11.2-q13.1 Interstitial Duplication with Maternal Somatic Mosaicism, Renal Carcinoma, and Autism. Frontiers in Genetics, 2016, 7, 205.	2.3	4

#	Article	IF	Citations
37	Case 27-2018: A 3-Year-Old Boy with Seizures. New England Journal of Medicine, 2018, 379, 870-878.	27.0	4
38	Multisite Semiautomated Clinical Data Repository for Duplication 15q Syndrome: Study Protocol and Early Uses. JMIR Research Protocols, 2017, 6, e194.	1.0	4
39	Teaching NeuroImage: Notched Delta and Angelman Syndrome. Neurology, 2021, 97, e1543-e1544.	1.1	3
40	Rufinamide treatment for refractory epilepsy in a largely pediatric population. Journal of Pediatric Epilepsy, 2015, 01, 097-101.	0.2	2
41	Clinical report and biochemical analysis of a patient with fumarate hydratase deficiency. American Journal of Medical Genetics, Part A, 2020, 182, 504-507.	1.2	2
42	Biochemical Analysis of a Patient with Fumarate Hydratase Deficiency. FASEB Journal, 2021, 35, .	0.5	0
43	Biochemical Analysis of a Patient with Fumarate Hydratase Deficiency. FASEB Journal, 2020, 34, 1-1.	0.5	0